Search
Now showing items 11-18 of 18
Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?
(Lippincott Williams & Wilkins, 2008)
Background: A pruritic papular eruption (PPE) is a common skin manifestation observed in 12–46% of persons with HIV infection living in tropical countries. Objective: To determine whether PPE responds to HAART and whether ...
Free antiretrovirals must not be restricted only to treatment-naive patients: experience in Uganda suggests that restricting access is not the way forward
(Public Library of Science, 2005-10)
No Abstract
Cause-Specific Mortality and the Contribution of Immune Reconstitution Inflammatory Syndrome in the First 3 Years after Antiretroviral Therapy Initiation in an Urban African Cohort
(Infectious Diseases Society of America, 2009)
Background. Although many studies have reported high early mortality among patients enrolled in antiretroviral therapy (ART) programs in sub-Saharan Africa—particularly among those individuals with advanced immunodeficiency— ...
Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, Uganda
(International Journal of STD & AIDS, 2009)
Antiretroviral treatment roll-out programmes in Africa often have difficulties to cope with the increasing number of clients. Based on the findings of a survey carried out in 2005 that showed long waiting times, innovative ...
Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
(Open Learning on Enteric Pathogens, 2009-03)
A large number of patients are switched to second-line antiretroviral therapy, especially in resource limited settings. Lopinavir/Ritonavir is the main drug used in second-line treatment regimens. We describe a patient ...
Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a Resource-Limited Setting (Uganda).
(University of Chicago Press, 2007-08-15)
We describe 24 Ugandan patients with human immunodeficiency virus infection who developed symptomatic hyperlactatemia associated with the use of nucleoside analogues. All patients were receiving combination therapy that ...
HIV Eosinophilic Folliculitis in Uganda
(American Medical Association (AMA), 2006)
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
(Elsevier, 2022-04-20)
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs)
for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed to ...